logo-loader
RNS
viewFaron Pharmaceuticals Ltd

Update on Traumakine drug substance manufacturing

/**/ link{ color: blue }visited{ color: #954F72 } .af{size:595.0pt 842.0pt;margin:127.6pt 2.0cm 90.7pt 2.0cm;}div.af{}p.bd{margin:0cm;margin-bottom:.0001pt;line-height:16.0pt;text-autospace:ideograph-other;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%; margin-right: 7.1pt; text-align: center}span.bb{font-size:11.0pt;line-height:115%;font-family: "Calibri","sans-serif"}p.be{margin:0cm;margin-bottom:.0001pt;line-height:16.0pt;text-autospace:ideograph-other;font-size:10.0pt;font-family:"Arial","sans-serif";line-height: 115%; margin-right: 7.1pt; text-align: center}p.bf{margin:0cm;margin-bottom:.0001pt;line-height:16.0pt;text-autospace:ideograph-other;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 150%}span.ay{font-size:11.0pt; line-height:150%;font-family:"Calibri","sans-serif"}p.bg{margin:0cm;margin-bottom:.0001pt;line-height:16.0pt;text-autospace:ideograph-other;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 150%; text-align: center}span.aw{font-size:12.0pt;line-height:150%;font-family:"Calibri","sans-serif"}p.bh{margin:0cm;margin-bottom:.0001pt;line-height:16.0pt;text-autospace:ideograph-other;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%; text-align: justify; text-justify: inter-ideograph} p.bi{margin:0cm;margin-bottom:.0001pt;line-height:16.0pt;text-autospace:ideograph-other;font-size:10.0pt;font-family:"Arial","sans-serif";text-align:justify;text-justify:inter-ideograph; line-height:115%}span.at{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}p.bj{margin:0cm;margin-bottom:.0001pt;line-height:16.0pt;text-autospace:ideograph-other;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%}span.ar{font-size:11.0pt; line-height:115%;font-family:"Calibri","sans-serif"}p.bk{margin:0cm;margin-bottom:.0001pt;line-height:16.0pt;text-autospace:ideograph-other;font-size:10.0pt;font-family:"Arial","sans-serif";line-height:115%}p.bl{margin:0cm;margin-bottom:.0001pt;text-autospace:ideograph-other;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%}p.bm{margin:0cm;margin-bottom:.0001pt;text-autospace:ideograph-other;font-size:12.0pt;font-family:"Cambria","serif";line-height:115%}span.ao{font-size:11.0pt; line-height:115%;font-family:"Calibri","sans-serif";color:black}span.an{font-size: 11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}span.am{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"; color:black} p.bn{margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:0cm;text-autospace:ideograph-other;font-size:10.0pt;font-family:"Times","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph;line-height:115%}p.bo{margin:0cm;margin-bottom:.0001pt;text-autospace:ideograph-other;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; text-align: justify; text-justify: inter-ideograph}span.ak{font-size:11.0pt;line-height:115%;font-family: "Calibri","sans-serif";color:black}p.bp{margin:0cm;margin-bottom:.0001pt;text-autospace:ideograph-other;font-size:12.0pt;font-family:"Cambria","serif";text-align:justify;text-justify:inter-ideograph; line-height:115%}span.aj{font-size: 11.0pt;line-height:115%;font-family:"Calibri","sans-serif";color:black}span.bq{color:blue;text-decoration:underline;font-size:11.0pt; line-height:115%;font-family:"Calibri","sans-serif"}p.br{margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:0cm;text-autospace:ideograph-other;font-size:10.0pt;font-family:"Times","serif";font-weight: bold; line-height: 115%; margin: 0cm; margin-bottom: .0001pt; text-align: justify; text-justify: inter-ideograph}p.bs{margin:0cm;margin-bottom:.0001pt;line-height:16.0pt;text-autospace:ideograph-other;font-size:10.0pt;font-family:"Arial","sans-serif";text-align:justify;text-justify:inter-ideograph; line-height:120%}span.ah{font-size:11.0pt;line-height:120%;font-family: "Calibri","sans-serif";color:black} /**/
RNS Number : 4268O
Faron Pharmaceuticals Oy
02 October 2019
 

Faron Pharmaceuticals Oy

("Faron" or the "Company")

 

Update on Traumakine drug substance manufacturing

 

TURKU - FINLAND, 02 October 2019 - Faron Pharmaceuticals Oy (AIM: FARN), the clinical stage biopharmaceutical company, announces that further to the update provided in the H1 2019 interim results in relation to the active pharmaceutical ingredient ("API") manufacturing process for Traumakine, Rentschler Biopharma SE ("Rentschler") has sent Faron a letter in which Rentschler states that it terminates the agreement concerning the API manufacturing. It is the Company's understanding that this relates to the fact that significant upgrading of the API manufacturing process would be required prior to MAA/BLA approval for Traumakine.

 

The Company is exploring various options for future API manufacturing. This termination has no impact on the currently on-going clinical advice process with FDA/EMA, which focuses on the structure of the next Traumakine clinical study.

 

 

For more information please contact:

 

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

[email protected] 

 

Panmure Gordon (UK) Limited, Nomad and Broker

Emma Earl, Freddy Crossley (Corporate Finance)

James Stearns (Corporate Broking)

Phone: +44 207 886 2500

 

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: [email protected]

 

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: [email protected]

 

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS) and progressing in phase II trial for the Rupture of Abdominal Aorta Aneurysm ("RAAA"). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine. Faron is based in Turku, Finland. Further information is available at www.faron.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBFLLBKBFBFBQ

Quick facts: Faron Pharmaceuticals Ltd

Price: 192.5

Market: AIM
Market Cap: £83.33 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18

RNS